Clinical trials: Allergic Rhinoconjunctivitis
Rhinoconjunctivitis With or Without Allergic Asthma
Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With House Dust Mites
Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerised With House Dust Mite in pediatric allergic patients
- Trial name
- NCT03963947
- Testing
- Beltavac® Polymerized with house dust mites
- Where
- Spain
- Volunteers
- 97 people
- Sponsor
- Alfons Malet i Casajuana
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis
This is a Phase 2a study to evaluate the efficacy and safety of Norketotifen (NKT) in subjects with allergic rhinitis.
- Trial name
- NCT03887026
- Testing
- Norketotifen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Emergo Therapeutics, Inc.
Birch Pollen Allergy, Allergic Rhinoconjunctivitis
S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen
The aim of this clinical phase I single centre, randomized, double-blind, placebo-controlled study with open comparator is to investigate tolerability and safety as well as the immunological effects of BM41 in comparison to…
- Trial name
- BM41 (NCT04912076)
- Testing
- BM41, ALK Alutard SQ Betula verrucosa
- Where
- Denmark
- Volunteers
- 47 people
- Sponsor
- Odense University Hospital
Allergic Rhinoconjunctivitis, Allergic Rhinitis
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
A research study of house dust mite (HDM) SLIT-tablet for the treatment of HDM allergy in Chinese participants aged 12-65.
- Trial name
- NCT07060885
- Testing
- HDM SLIT-tablet (12 SQ-HDM)
- Where
- 30 sites in China
- Volunteers
- 327 people
- Sponsor
- ALK-Abelló A/S
Birch Pollen-related Rhinoconjunctivitis, Rhinitis, Allergic, Seasonal
Study of rBet v1 Tablets
The purpose of this study is to determine the efficacy and safety of three doses of r Bet v1 administered as sublingual tablets in birch pollen allergic subjects.
- Trial name
- NCT00901914
- Testing
- rBet v 1
- Where
- 8 sites in Denmark, Finland and 6 more
- Volunteers
- 483 people
- Sponsor
- Stallergenes Greer
Rhinitis, Allergic, Seasonal
Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever
The purpose of this study is to determine at which point in the dosing regime grass pollen immunotherapy causes a significant reduction in the late skin response to allergen challenge.
- Trial name
- NCT00135629
- Testing
- Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ)., Venepuncture: 100ml blood sample taken on 12 separate visits
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Imperial College London
Allergic Rhinoconjunctivitis
Study of BLU-808 in Allergic Rhinoconjunctivitis
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic…
- Trial name
- NCT06922448
- Testing
- BLU-808
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Blueprint Medicines Corporation
Seasonal Allergic Rhinitis
A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine
The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.
- Trial name
- NCT01108783
- Testing
- Bilastine, Desloratadine
- Volunteers
- 720 people
- Sponsor
- Faes Farma, S.A.
Allergic Rhinitis Due to Grass Pollens
Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate
This trial is an exploratory randomised, parallel-group, double-blind, placebo- controlled, national, single-centre trial. The trial will be initiated before 2013 grass pollen season and subjects will be randomised in September…
- Trial name
- NCT01854736
- Testing
- Grazax
- Where
- 2 sites in Spain
- Volunteers
- 51 people
- Sponsor
- ALK-Abelló A/S
Allergy
A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis
This is a 2 year clinical study to compare 5-grass mix SLIT-drops with placebo in relieving grass pollen-induced rhinoconjunctivitis symptoms and in use of symptom-relieving medication during the second grass pollen season (peak…
- Trial name
- Rhapsody (NCT04881461)
- Testing
- 5-grass mix SLIT-drops
- Where
- 48 sites in Czechia, Estonia and 4 more
- Volunteers
- 445 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis, Allergy to Pollen
Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber
The aim of this study is to assess the nasal and conjunctival response in subjects allergic to birch pollen during controlled exposures in the ALYATEC environmental exposure chamber (EEC)
- Conditions
- Allergic Rhinitis, Allergy to Pollen, Rhinoconjunctivitis
- Trial name
- NCT04583202
- Testing
- Exposure to allergen
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Alyatec
Dust Mite Allergy, Allergic Rhinitis
Impact of a Novel Immune Modulating Dietary Supplement on House Dust Mite Induced Allergic Rhinoconjunctivitis
A validated mobile Allergen exposure chamber (AEC) is used to expose qualified study participants suffering from house dust mite (HDM) induced allergic rhinoconjunctivitis.
- Trial name
- NCT04477382
- Testing
- holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, is loaded with ligands such as retinoic acid, zinc and polyphenol-iron complexes.
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Ecarf Institute GmbH
Rhinoconjunctivitis, Grass Allergy
ToleroMune Grass Follow on Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT02292875
- Where
- 2 sites in Canada
- Volunteers
- 84 people
- Sponsor
- Circassia Limited
House Dust Mite Allergy, Perennial Allergic Rhinitis
Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis
Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate…
- Conditions
- House Dust Mite Allergy, Perennial Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- Trial name
- NCT05400811
- Testing
- MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)
- Where
- 16 sites in Spain
- Volunteers
- 400 people
- Sponsor
- Inmunotek S.L.
Allergic Rhinoconjunctivitis
A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects
This is a continuing research study of a vaccine for allergy to Japanese Red Cedar. The vaccine is called CryJ2-DNA-LAMP Plasmid vaccine.
- Trial name
- NCT01966224
- Testing
- CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Immunomic Therapeutics, Inc.
Allergic Rhinoconjunctivitis
Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House Dust Mites
The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy (SCIT) with House Dust Mite (HDM) extract in patients with rhinoconjunctivitis with or without associated mild asthma and sensitized to…
- Trial name
- NCT02881879
- Testing
- Allergovac depot DPT/DF (50:50)
- Where
- 5 sites in Spain
- Volunteers
- 43 people
- Sponsor
- Roxall Medicina España S.A
Allergic Rhinoconjunctivitis, Chronic Urticaria
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
The conduct of this clinical trial is aimed at determining the most suitable dose regimen for children in different age groups, and secondarily to assess the safety and tolerability of bilastine in this paediatric population…
- Trial name
- NCT01081574
- Testing
- Bilastine
- Where
- 7 sites in Australia, Germany and 1 more
- Volunteers
- 36 people
- Sponsor
- Faes Farma, S.A.
Seasonal Allergic Rhinoconjunctivitis
Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis
The purpose of this study is to assess the safety and tolerability of gpASIT+TM administered subcutaneously in absence or in presence of an immunoregulating adjuvant in grass pollen allergic patients.
- Trial name
- NCT01111279
- Testing
- gpASIT+TM, gpAST+TM/adjuvant
- Where
- Belgium
- Volunteers
- 27 people
- Sponsor
- BioTech Tools S.A.
Allergy
Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis
To evaluate the safety and efficacy of SLIT compared with placebo for reduction of symptoms and rescue medication usage
- Trial name
- NCT00367640
- Testing
- 100 IR grass pollen allergen extract tablet, 300 IR grass pollen allergen extract tablet, 500 IR grass pollen allergen extract tablet
- Volunteers
- 628 people
- Sponsor
- Stallergenes Greer
Seasonal Allergic Rhinitis, Asthma
Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma
The purpose of this study is to determine whether it is safe to administer Ragweed-SPIRE to subjects suffering from both ragweed allergy and asthma.
- Trial name
- NCT02061670
- Testing
- Ragweed-SPIRE
- Where
- 5 sites in Canada
- Volunteers
- 55 people
- Sponsor
- Circassia Limited